EUVIMEDEUVIMED entdecken
Crossref

Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial

Byshetty Rajendar iD, Jeewan Ram Vishnoi iD, Nivedita Sharma iD, Dharma Ram Poonia iD, Rahul Yadav iD, Taruna Yadav iD, Poonam Elhence iD, Puneet Pareek iD, Sanjeev Misra iD

World Journal of Surgery · 16.11.2026

DOI: 10.1002/wjs.70696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Surgery, online erschienen am 16.11.2026. Verfasst von Byshetty Rajendar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Surgical Oncology, TX Hospital, Hyderabad, India. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sentinel lymph node biopsy is standard for staging clinically node‐negative (cN0) breast cancer, but the dual tracer gold‐standard radioisotope–blue dye technique is unavailable in resource‐limited settings. Fluorescein, an inexpensive, safe, visible‐light tracer, has no randomized data after neoadjuvant chemotherapy (NACT). We compared fluorescein–methylene blue with methylene blue alone for sentinel lymph node biopsy in post‐NACT cN0 patients and, secondarily, assessed the accuracy of axillary ultrasound.

Methods

In this randomized pilot feasibility trial, post‐NACT cN0 breast cancer patients were randomized 1:1 to fluorescein–methylene blue (FlaB) or methylene blue alone after dye allergy testing. All patients underwent completion axillary lymph node dissection as the reference standard. Identification rate and false‐negative rate were estimated with 95% confidence intervals.

Results

Of 136 patients who received NACT, 62 (45.6%) had a clinical complete nodal response and were recruited; 2 (3.2%) were excluded for methylene blue allergy, leaving 30 randomized per group, with all 60 completing the protocol. IR: 93.3% (28/30; 95% CI, 78.7–98.1) with FlaB versus 83.3% (25/30; 95% CI, 66.4–92.7) with methylene blue alone (difference, 10.0 percentage points; p = 0.23). FNR: 11.1% (2/18; 95% CI, 3.1–32.8) versus 12.5% (2/16; 95% CI, 3.5–36.0; p = 0.87). On secondary analysis, axillary ultrasound was normal in 30 of 62 patients (48.4%) and suspicious in 32 (51.6%); against final pathology, its sensitivity was 80.6%, and its negative predictive value was 76.7%; 7 of the 36 node‐positive patients (19.4%) had a sonographically normal axilla. No dye‐related adverse events occurred.

Conclusion

FlaB achieved an identification rate above the 90% benchmark and a false‐negative rate comparable to radioisotope‐based dual‐tracer series. Axillary ultrasound did not reliably exclude residual nodal disease (negative predictive value 76.7%) and cannot replace pathological nodal staging after NACT. Fluorescein–methylene blue is a safe, radioisotope‐free dual‐tracer strategy for SLNB in resource‐limited settings.

Schlagwörter

Stichwörter der Autor:innen

axillary ultrasoundbreast cancerfluoresceinmethylene blueneoadjuvant chemotherapypilot studysentinel lymph node biopsy

Autor:innen und Institutionen

  • Surgical Oncology, TX Hospital, Hyderabad, India.
  • Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India.
  • Surgical Oncology, Apex Hospitals, Jaipur, India.
  • Department of Diagnostic and Interventional Radiology, All India Institute of Medical Sciences, Jodhpur, India.
  • Department of Pathology, All India Institute of Medical Sciences, Jodhpur, India.
  • Department of Radiation Oncology, All India Institute of Medical Sciences, Jodhpur, India.

ORCID-Profile: Byshetty Rajendar, Jeewan Ram Vishnoi, Nivedita Sharma, Dharma Ram Poonia, Rahul Yadav, Taruna Yadav, Poonam Elhence, Puneet Pareek, Sanjeev Misra

Zitieren

APA

Rajendar, B., Vishnoi, J. R., Sharma, N., Poonia, D. R., Yadav, R., Yadav, T., Elhence, P., Pareek, P., & Misra, S. (2026). Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial. World Journal of Surgery. https://doi.org/10.1002/wjs.70696

Vancouver

Rajendar B, Vishnoi JR, Sharma N, Poonia DR, Yadav R, Yadav T, et al. Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial. World Journal of Surgery. 2026. doi:10.1002/wjs.70696

BibTeX
@article{Rajendar2026,
  author = {Rajendar, Byshetty and Vishnoi, Jeewan Ram and Sharma, Nivedita and Poonia, Dharma Ram and Yadav, Rahul and Yadav, Taruna and Elhence, Poonam and Pareek, Puneet and Misra, Sanjeev},
  title = {Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial},
  journal = {World Journal of Surgery},
  year = {2026},
  doi = {10.1002/wjs.70696}
}
Kostenlos starten →